Navigation Links
Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
Date:8/19/2008

MUMBAI, India and BALTIMORE, Aug. 19 /PRNewswire/ -- Lupin Ltd. announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus(R) line of products with Forest Laboratories, Inc. Under the terms of the agreement, Lupin Pharmaceuticals, Inc., USA, will use its 50 person sales force to promote the product to pediatricians.

AeroChamber Plus(R) is a Valved Holding Chamber (VHC) device that is used with metered dose inhalers to improve the delivery of medication to the lungs in the treatment of asthma and COPD. AeroChamber Plus(R) also reduces the deposition of medication in the mouth and throat and makes metered dose inhalers easier for patients to use by reducing the need to coordinate actuation of the inhaler with inhalation. AeroChamber Plus(R) is the most widely prescribed holding chamber in the United States and has been used by millions of patients since its introduction. Approximately two thirds of AeroChamber Plus(R) Valved Holding Chamber prescriptions (IMS 2007 data) are written by pediatricians.

"We are happy to strike this alliance with Forest. While the AeroChamber Plus(R) brand has a strong position in the Valved Holding Chamber market, we believe that this marketing alliance presents a significant opportunity for further growth of the franchise for Forest, resulting in value for both companies," said Vinita Gupta, President, LPI.

This agreement with Forest Laboratories, Inc. reflects Lupin's commitment to bring value additions to the US market to improve the overall health of the patient population. This alliance will also extend Lupin's presence in the respiratory segment and help strengthen its franchise with pediatricians.

About Lupin

Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is the wholly owned U.S. subsidiary of Mumbai based Lupin Limited, a leading Indian Pharmaceutical company. Lupin Limited develops, manufactures and markets a wide range of quality, affordable generic and branded generic formulations and APIs for the developed and the developing markets of the world. Twelve of Lupin's facilities have been inspected and approved by the U.S. Food & Drug Administration.

For the year ended March 2008, the Lupin's consolidated Revenues and Profit after Tax were Rs. 27730 million (USD 660.23 million) and Rs. 4083 million (USD 102 million) respectively.

The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. Currently positioned amongst the top five pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders.

AeroChamber Plus(R) is a registered trademark of Trudell-Monaghan.

For More Information:

Lupin Pharmaceuticals, Inc.

Contact: Atul Gokhale

General Manager - Marketing

410-576-2000

Web site: http://www.lupinpharmaceuticals.com.


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
2. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
3. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
4. Lupin Launches Ramipril Capsules
5. Lupin Receives USFDA Approval for Topiramate Tablets
6. Older Patients Less Likely to Be Taken to Trauma Centers
7. VA Opening Rural Health Resource Centers
8. AUDIO from Medialink and Pfizer: Community Health Centers Celebrated for Making Quality Care Available to Uninsured Americans
9. Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County
10. IPC The Hospitalist Company Enters Ohio and Pennsylvania Markets
11. Bederra Corp.s Lumar Imaging Division Enters Into Joint Venture With Basic Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting ... family, friends, and community. “Coming Home 2017” will be held on Friday ...
(Date:1/20/2017)... ... ... New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is ... be wheeled out of the way and stored when not in use. It is freestanding ... feedback from customers into specific enhancements and created a new product that is built directly ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Bionic Sports Nutrition ... walks of life, announced it had a successful January ECRM Trade Show in Hilton ... the United States, which allows it to provide its products to all clients at ...
(Date:1/20/2017)... ... , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are ... Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 ... flare and light leak transitions have a very high-dynamic range for super smooth falloff. ...
(Date:1/20/2017)... ... January 20, 2017 , ... “I Forgive You”: a fine examination of how ... You” is the creation of published author, Stephen Miller, who, for over ten long years ... given to him. Born in Trinidad and Tobago, he has been serving the Lord for ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... The global immunomodulators market is expected ... to a new study by Grand View Research, ... driven by high R&D investments employed by the ... new and therapeutically advanced drugs. This is believed ... unprecedented rate into the immunomodulators market hence providing ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Alzheimer,s ... Leading Companies – our new study reveals trends, R&D ... and events affecting the Alzheimer,s disease therapeutics and diagnostics ... these key questions: - How is the Alzheimer,s disease ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
Breaking Medicine Technology: